Dr. Fendler on Rationale for Creating the 68Ga-PSMA-11 PET in Prostate Cancer

Video

In Partnership With:

Wolfgang Fendler, MD, discusses the rationale for creating the 68Ga-PSMA-11 PET in prostate cancer.

Wolfgang Fendler, MD, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, discusses the rationale for creating the 68Ga-PSMA-11 PET imaging test in prostate cancer.

The 68Ga-PSMA-11 PET test, a whole-body scan for patients with prostate cancer, offers insight into tumor location and provides other relevant information in the clinical setting. Knowing the location of the tumor is vital for many available treatments for this disease, including radiation and surgery.

What had once been an unmet need in the prostate cancer paradigm has now been filled with the the development of the 68Ga-PSMA-11 PET imaging test; this test can help improve future prostate cancer regimens, concludes Fendler.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS